Androgenic Alopecia Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other - Product Image

Androgenic Alopecia Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other

  • ID: 4451358
  • Report
  • 112 pages
  • P&S Market Research
1 of 4

FEATURED COMPANIES

  • Allergan plc
  • Almirall, S.A.
  • Merck & Co., Inc.
  • MORE
Androgenic alopecia currently exhibits a growing pipeline with approximately 24 active drug candidates.

Androgenic Alopecia Therapeutics Pipeline in 2017

The study analyzed that the androgenic alopecia therapeutics pipeline comprises approximately 24 active drug candidates in different stages of development. Androgenic alopecia is a genetic disorder that affects both men and women and is characterized by hair loss in both the sexes. Androgenic alopecia is also known as male-pattern baldness in men and female-pattern baldness in women. The predisposing factors for androgenic alopecia include allergies, burns, irritants, injuries, infections, and toxins.

Various Technologies are Being Used for Androgenic Alopecia

According to the research findings, various new technology platforms are being used by the companies for developing drug candidates to treat the disease. For instance, KINect technology platform, a kinase-focused drug discovery technology platform is used to manufacture, soft Janus kinase inhibitors, a Pre-Clinical drug candidate by Aclaris Therapeutics, Inc.

Positive Clinical Results of Androgenic Alopecia Therapeutics Candidates

The positive clinical results of androgenic alopecia drug candidates have been driving the pipeline growth. Many drug candidates have shown positive clinical results and are proceeding further towards development. In February 2016, Cassiopea S.p.A. reported the top-line results from the proof of concept, Phase II clinical trial of Breezula (CB-03-01), in androgenic alopecia and it was found that Breezula, met both its two pre-defined co-primary efficacy endpoints, increase in total area hair count within 1 cm2 (TAHC) and subject hair growth assessment (HGA) at six months. Breezula also demonstrated favorable safety profile.

Various Collaborations for Androgenic Alopecia Therapeutics Drug Development

In August 2017, Aclaris Therapeutics, Inc. acquired Confluence Life Sciences, Inc., a privately held biotechnology company for a consideration of $10 million in cash and issued approximately 350,000 shares of its common stock, with a value of approximately $10 million on the closing date to expand the dermatological pipeline of Aclaris Therapeutics, Inc.

Some of the key players developing drugs for the treatment of androgenic alopecia therapeutics include GlaxoSmithKline plc, Almirall S.A., Allergan plc, RepliCel Life Sciences Inc. and others.

Androgenic Alopecia Therapeutics Pipeline Analysis
  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan plc
  • Almirall, S.A.
  • Merck & Co., Inc.
  • MORE
"Chapter 1. Research Background
1.1. Research Objectives
1.2. Definition
1.3. Research Scope
1.3.1. Pipeline Analysis by Phase
1.3.2. Pipeline Analysis by Route of Administration
1.3.3. Pipeline Analysis by Molecule Type
1.3.4. Pipeline Analysis by Target
1.4. Key Stakeholders

Chapter 2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.2.1. Breakdown of Primary Research Respondents
2.2.1.1. By industry participants
2.2.1.2. By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook
4.1. Androgenic Alopecia Overview
4.1.1. Signs and Symptoms
4.1.2. Pathophysiology
4.1.3. Diagnosis
4.1.4. Treatment
4.1.5. Epidemiology
4.2. Key Drivers
4.3. Key Barriers
4.4. Androgenic Alopecia Therapeutics Pipeline Analysis
4.4.1. Pipeline Analysis by Phase
4.4.2. Pipeline Analysis by Route of Administration
4.4.3. Pipeline Analysis by Molecule Type
4.4.4. Pipeline Analysis by Target
4.4.5. Pipeline Analysis by Company

Chapter 5. Androgenic Alopecia Therapeutics Pipeline Analysis by Phase (2017)
5.1. Phase III: Drug Profiles
5.1.1. P-3074
5.1.1.1. Pre-Clinical Studies
5.1.1.2. Clinical Trials
5.1.1.3. Clinical Results
5.1.1.4. Strategic Developments
5.1.1.5. Designations
5.1.1.6. Grants
5.1.1.7. Patents
5.1.1.8. Technology
5.2. Phase II: Drug Profiles
5.2.1. SM04554
5.2.1.1. Pre-Clinical Studies
5.2.1.2. Clinical Trials
5.2.1.3. Clinical Results
5.2.1.4. Strategic Developments
5.2.1.5. Designations
5.2.1.6. Grants
5.2.1.7. Patents
5.2.1.8. Technology
5.3. Phase I: Drug Profiles
5.3.1. RCH-01
5.3.1.1. Pre-Clinical Studies
5.3.1.2. Clinical Trials
5.3.1.3. Clinical Results
5.3.1.4. Strategic Developments
5.3.1.5. Designations
5.3.1.6. Grants
5.3.1.7. Patents
5.3.1.8. Technology
5.4. Pre-Clinical: Drug Profiles
5.4.1. BMD-1141
5.4.1.1. Pre-Clinical Studies
5.4.1.2. Strategic Developments
5.4.1.3. Designations
5.4.1.4. Grants
5.4.1.5. Patents
5.4.1.6. Technology
5.5. Discovery: Drug Profiles
5.5.1. Small Molecules to Inhibit JAK to Treat Androgenetic Alopecia
5.5.1.1. Strategic Developments
5.5.1.2. Designations
5.5.1.3. Grants
5.5.1.4. Patents
5.5.1.5. Technology
5.6. Discontinued: Drug Profiles
5.6.1. Discontinued Drugs
5.6.1.1. Pre-Clinical Studies
5.6.1.2. Clinical Trials
5.6.1.3. Clinical Results
5.6.1.4. Strategic Developments
5.6.1.5. Designations
5.6.1.6. Grants
5.6.1.7. Patents
5.6.1.8. Technology

Chapter 6. Clinical Trials Analysis
6.1. Clinical Trials Analysis by Region
6.2. Clinical Trials Analysis by Trial Status

Chapter 7. Competitive Landscape Analysis
7.1. Key Players Benchmarking for Androgenic Alopecia Therapeutics Pipeline
7.2. SWOT Analysis of Androgenic Alopecia Therapeutics Pipeline

Chapter 8. Company Profiles
8.1. Merck & Co., Inc.
8.1.1. Business Overview
8.1.2. Product and Service Offerings
8.2. Allergan plc
8.2.1. Business Overview
8.2.2. Product and Service Offerings
8.3. Almirall, S.A.
8.3.1. Business Overview
8.3.2. Product and Service Offerings
8.4. RepliCel Life Sciences Inc.
8.4.1. Business Overview
8.4.2. Product and Service Offerings
8.5. RiverTown Therapeutics, Inc.
8.5.1. Business Overview
8.5.2. Product and Service Offerings

Chapter 9. Appendix
9.1. Abbreviations
9.2. Related Reports
Note: Certain sections of the above table of contents would vary according to the availability of information."
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Merck & Co., Inc.
  • Allergan plc
  • Almirall, S.A.
  • RepliCel Life Sciences Inc.
  • RiverTown Therapeutics, Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll